ATE466864T1 - Nichtaggregierende, nichtausschaltende oligomere, nukleotid-analoga enthaltend; verfahren zu deren herstellung und verwendung - Google Patents

Nichtaggregierende, nichtausschaltende oligomere, nukleotid-analoga enthaltend; verfahren zu deren herstellung und verwendung

Info

Publication number
ATE466864T1
ATE466864T1 AT00980769T AT00980769T ATE466864T1 AT E466864 T1 ATE466864 T1 AT E466864T1 AT 00980769 T AT00980769 T AT 00980769T AT 00980769 T AT00980769 T AT 00980769T AT E466864 T1 ATE466864 T1 AT E466864T1
Authority
AT
Austria
Prior art keywords
aggregative
official
production
nucleotide analogs
oligomers containing
Prior art date
Application number
AT00980769T
Other languages
English (en)
Inventor
Alexander Gall
Igor Kutyavin
Nicolaas Vermeulen
Robert Dempcy
Original Assignee
Epoch Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epoch Biosciences Inc filed Critical Epoch Biosciences Inc
Application granted granted Critical
Publication of ATE466864T1 publication Critical patent/ATE466864T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003Peptide-nucleic acids (PNAs)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6832Enhancement of hybridisation reaction
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6816Hybridisation assays characterised by the detection means
    • C12Q1/6818Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AT00980769T 1999-11-23 2000-11-21 Nichtaggregierende, nichtausschaltende oligomere, nukleotid-analoga enthaltend; verfahren zu deren herstellung und verwendung ATE466864T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/447,936 US6660845B1 (en) 1999-11-23 1999-11-23 Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
PCT/US2000/032265 WO2001038584A2 (en) 1999-11-23 2000-11-21 Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof

Publications (1)

Publication Number Publication Date
ATE466864T1 true ATE466864T1 (de) 2010-05-15

Family

ID=23778351

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00980769T ATE466864T1 (de) 1999-11-23 2000-11-21 Nichtaggregierende, nichtausschaltende oligomere, nukleotid-analoga enthaltend; verfahren zu deren herstellung und verwendung

Country Status (9)

Country Link
US (3) US6660845B1 (de)
EP (1) EP1232157B1 (de)
JP (1) JP2003527579A (de)
AT (1) ATE466864T1 (de)
AU (1) AU1798901A (de)
CA (1) CA2392033C (de)
DE (1) DE60044367D1 (de)
ES (1) ES2344337T3 (de)
WO (1) WO2001038584A2 (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083813A1 (en) * 2000-05-02 2001-11-08 Centre National De La Recherche Scientifique Identification of genetic markers
CA2413556A1 (en) * 2000-06-23 2001-12-27 Yissum Research Development Company Of The Hebrew University In Jerusale M Positively-charged peptide nucleic acid analogs with improved properties
WO2002008414A1 (en) * 2000-06-27 2002-01-31 National Institute Of Advanced Industrial Science And Technology Novel nucleic acid probes and method of assaying nucleic acid by using the same
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US20030082547A1 (en) 2001-08-27 2003-05-01 Ewing Gregory J. Non-fluorescent quencher compounds and biomolecular assays
US6972339B2 (en) 2001-09-07 2005-12-06 Epoch Biosciences, Inc. Compounds and methods for fluorescent labeling
US8569516B2 (en) * 2001-09-07 2013-10-29 Elitech Holding B.V. Compounds and methods for fluorescent labeling
AU2002343604C1 (en) 2001-10-30 2009-09-17 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
WO2003040395A2 (en) 2001-11-07 2003-05-15 Applera Corporation Universal nucleotides for nucleic acid analysis
JP2005517900A (ja) 2001-11-21 2005-06-16 アプレラ コーポレイション デジタルアッセイ
WO2003065146A2 (en) 2002-01-25 2003-08-07 Applera Corporation Methods for placing, accepting, and filling orders for products and services
JP4481656B2 (ja) * 2002-02-27 2010-06-16 ライフ テクノロジーズ コーポレーション 3’→5’エキソヌクレアーゼ耐性クエンチャードメインを含むfet標識オリゴヌクレオチドを使用する方法およびそれを実施するための組成物
US6818420B2 (en) 2002-02-27 2004-11-16 Biosource International, Inc. Methods of using FET labeled oligonucleotides that include a 3′-5′ exonuclease resistant quencher domain and compositions for practicing the same
KR100860136B1 (ko) 2003-01-14 2008-09-25 길리애드 사이언시즈, 인코포레이티드 복합 항바이러스 치료를 위한 조성물 및 방법
US7429596B2 (en) * 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
CA2533966A1 (en) 2003-07-30 2005-02-10 Gilead Sciences, Inc. Nucleobase phosphonate analogs for antiviral treatment
EP2145888A1 (de) 2003-09-18 2010-01-20 Conforma Therapeutics Corporation Deazapurinderivate als HSP90-Inhibitoren
US7541454B2 (en) * 2003-10-24 2009-06-02 Epoch Biosciences, Inc. Compounds and methods for fluorescent labeling
ES2529256T3 (es) * 2003-10-28 2015-02-18 Epoch Biosciences, Inc. Sondas fluorescentes para la detección de ADN mediante hibridación con una sensibilidad mejorada y baja señal de fondo
ES2319648T3 (es) 2003-11-20 2009-05-11 Exiqon A/S Composicion atenuadora que comprende restos de antraquinona.
JP2007512838A (ja) 2003-12-01 2007-05-24 インヴィトロジェン コーポレーション 組換え部位を含む核酸分子およびその使用方法
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
EP1836319B1 (de) 2005-01-06 2012-09-19 Life Technologies Corporation Polypeptide mit nukleinsäurebindender aktivität sowie verfahren zur nukleinsäureamplifikation
US20060153745A1 (en) * 2005-01-11 2006-07-13 Applera Corporation Fluid processing device for oligonucleotide synthesis and analysis
MX2007011903A (es) 2005-03-30 2007-12-05 Conforma Therapeutics Corp Alquinil pirrolopirimidinas y analogos relacionados como inhibidores de hsp90.
US20070059713A1 (en) 2005-09-09 2007-03-15 Lee Jun E SSB-DNA polymerase fusion proteins
CN103215248B (zh) 2005-10-03 2016-05-18 应用生物系统有限责任公司 用于扩增核酸的组合物、方法和试剂盒
US9677123B2 (en) 2006-03-15 2017-06-13 Siemens Healthcare Diagnostics Inc. Degenerate nucleobase analogs
JP2009532507A (ja) * 2006-04-04 2009-09-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Pi3キナーゼアンタゴニスト
WO2008005542A2 (en) 2006-07-07 2008-01-10 Gilead Sciences, Inc., Antiviral phosphinate compounds
BRPI0715346A2 (pt) 2006-08-01 2013-11-26 Applera Corp Detecção de analitos e ácidos nucléicos
US9938641B2 (en) 2006-12-18 2018-04-10 Fluidigm Corporation Selection of aptamers based on geometry
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
WO2009067628A1 (en) 2007-11-20 2009-05-28 Applied Biosystems Inc. Reversible di-nucleotide terminator sequencing
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2010007418A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
EP3009436B1 (de) 2008-07-08 2019-06-05 Intellikine, LLC Kinasehemmer und verwendungsverfahren
CN105717176A (zh) 2008-09-02 2016-06-29 多伦多大学董事局 纳米结构的微电极以及集成所述微电极的生物传感器件
US20110171649A1 (en) * 2008-09-10 2011-07-14 Igor Kutyavin Detection of nucleic acids by oligonucleotide probes cleaved in presence of endonuclease v
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
AU2009305669A1 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
TW201100427A (en) 2009-03-31 2011-01-01 Arqule Inc Substituted heterocyclic compounds
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン, エルエルシー 複素環式化合物およびその使用
EP2432796B1 (de) 2009-05-21 2016-08-17 Siemens Healthcare Diagnostics Inc. Universaltags mit nicht-natürlichen nukleobasen
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
WO2011087707A1 (en) 2009-12-22 2011-07-21 Elitech Holding B.V. Hypertheromostable endonuclease iv substrate probe
AU2011255218B2 (en) 2010-05-21 2015-03-12 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2632920A1 (de) 2010-10-27 2013-09-04 Dynamix Pharmaceuticals Ltd. Sulfonamide zur modulation von pkm2
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ, インコーポレイテッド 複素環化合物及びその使用
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
JP5989668B2 (ja) 2011-01-11 2016-09-07 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント タンパク質検出方法
EP3369828B1 (de) * 2011-02-07 2020-07-15 The Governing Council Of The University Of Toronto Biosonden und verfahren zur verwendung davon
CA2828483A1 (en) 2011-02-23 2012-11-01 Intellikine, Llc Combination of kinase inhibitors and uses thereof
ES2799422T3 (es) 2011-03-10 2020-12-17 General Atomics Dispositivos y métodos de diagnóstico y preparación de muestras
EP2734530A1 (de) 2011-07-19 2014-05-28 Infinity Pharmaceuticals, Inc. Heterocyclische verbindungen und ihre verwendung
EP2734520B1 (de) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclische verbindungen und ihre verwendung
EP2548878A1 (de) * 2011-07-21 2013-01-23 Laboratorios Del. Dr. Esteve, S.A. Pyrazolo[3,4-d]pyrimidin-Verbindungen, deren Herstellung und Verwendung als Sigma-Liganden
JP6029668B2 (ja) 2011-08-29 2016-11-24 インフィニティー ファーマシューティカルズ, インコーポレイテッド 複素環式化合物及びその使用
JP6342805B2 (ja) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換ピラゾロ[3,4−d]ピリミジンおよびその用途
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP3354750A1 (de) 2012-07-18 2018-08-01 Siemens Healthcare Diagnostics Inc. Kit zur normalisierung von biologischen proben
WO2014028793A1 (en) * 2012-08-17 2014-02-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Cyclopentane-peptide nucleic acids for qualitative and quantitative detection of nucleic acids
SG11201502331RA (en) 2012-09-26 2015-04-29 Univ California Modulation of ire1
SMT201800561T1 (it) 2012-11-01 2018-11-09 Infinity Pharmaceuticals Inc Trattamento di cancri usando modulatori di isoforme di pi3 chinasi
US10590474B2 (en) 2013-03-11 2020-03-17 Elitechgroup B.V. Methods for true isothermal strand displacement amplification
US20140255928A1 (en) 2013-03-11 2014-09-11 Elitech Holding B.V. Methods for true isothermal strand displacement amplification
US10975423B2 (en) 2013-03-11 2021-04-13 Elitechgroup, Inc. Methods for true isothermal strand displacement amplification
WO2014175974A2 (en) 2013-03-13 2014-10-30 Elitech Holding B.V. Artificial nucleic acids
MX2015011944A (es) 2013-03-14 2015-12-01 Shire Human Genetic Therapies Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero.
DK2971098T3 (en) 2013-03-14 2019-02-18 Translate Bio Inc QUANTITATIVE ASSESSMENT FOR CAPE EFFECTIVENESS OF MESSENGER RNA
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
NZ718430A (en) 2013-10-04 2021-12-24 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
DK3119397T3 (da) 2014-03-19 2022-03-28 Infinity Pharmaceuticals Inc Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
WO2016053881A1 (en) 2014-10-03 2016-04-07 Life Technologies Corporation Genetic sequence verification compositions, methods and kits
WO2016090165A1 (en) 2014-12-03 2016-06-09 Life Technologies Corporation Charged reactive oligomers
CN107636165A (zh) 2015-01-12 2018-01-26 生命科技公司 用于核酸文库质量控制和定量的方法、系统和其组合物
MX390633B (es) 2015-09-14 2025-03-04 Infinity Pharmaceuticals Inc Formas solidas de derivados de isoquinolinona, proceso de fabricacion, composiciones que las contienen y metodos de uso de las mismas.
EP3368692B1 (de) 2015-10-29 2021-07-21 Temple University Of The Commonwealth System Of Higher Education Modifizierung von 3'-endstücken von nukleinsäuren durch dna-polymerase-theta
TWI747873B (zh) * 2016-02-01 2021-12-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG10201912456RA (en) 2016-06-24 2020-02-27 Infinity Pharmaceuticals Inc Combination therapies
US10738346B2 (en) 2017-03-09 2020-08-11 Elitechgroup, Inc. Nitrodiarylethenes as fluorescence quenchers for nucleic acid probes
WO2019036225A1 (en) 2017-08-17 2019-02-21 Elitechgroup, Inc. FLUORESCENCE EXTINGUISHERS STABILIZING DUPLEX FOR NUCLEIC PROBES
US11155713B2 (en) 2018-05-29 2021-10-26 Elitechgroup, Inc. Carborhodamine compounds and methods of preparation thereof
US12472198B2 (en) 2018-06-20 2025-11-18 Yale University RIG-I agonists and treatments using same
WO2021080629A1 (en) 2019-10-23 2021-04-29 Elitechgroup, Inc. Methods for true isothermal strand displacement amplification
AU2022284878A1 (en) 2021-06-04 2024-01-18 Translate Bio, Inc. Assay for quantitative assessment of mrna capping efficiency
CN115418395B (zh) * 2022-11-07 2023-01-17 百力格生物科技(上海)股份有限公司 Mgb探针溶解方法及其溶液
JP2025539043A (ja) 2022-11-14 2025-12-03 バイオンテック・エスイー Rnaキャッピング効率アッセイ
KR20260025139A (ko) 2023-06-14 2026-02-23 사노피 백신즈 유에스 인크. 메신저 rna의 캡핑 및 테일링 변형을 동시에 식별하거나 정량화하는 방법

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3529478A1 (de) 1985-08-16 1987-02-19 Boehringer Mannheim Gmbh 7-desaza-2'desoxyguanosin-nukleotide, verfahren zu deren herstellung und deren verwendung zur nukleinsaeure-sequenzierung
US5422251A (en) 1986-11-26 1995-06-06 Princeton University Triple-stranded nucleic acids
US6270961B1 (en) 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
DE3739366A1 (de) 1987-04-10 1988-10-27 Boehringer Mannheim Gmbh Desaza-purin-nucleosid-derivate, verfahren zu deren herstellung sowie deren verwendung bei der nucleinsaeure-sequenzierung sowie als antivirale mittel
US5824796A (en) 1988-09-28 1998-10-20 Epoch Pharmaceuticals, Inc. Cross-linking oligonucleotides
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
EP0472648A4 (en) 1989-05-18 1992-09-16 Microprobe Corporation Crosslinking oligonucleotides
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5177196A (en) * 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5512667A (en) 1990-08-28 1996-04-30 Reed; Michael W. Trifunctional intermediates for preparing 3'-tailed oligonucleotides
DE69132905T2 (de) 1990-12-06 2002-08-01 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Detektion von Nukleinsäuresequenzen
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5766855A (en) 1991-05-24 1998-06-16 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity and sequence specificity
DK51092D0 (da) * 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US5419966A (en) 1991-06-10 1995-05-30 Microprobe Corporation Solid support for synthesis of 3'-tailed oligonucleotides
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
CA2159630A1 (en) * 1993-03-30 1994-10-13 Philip D. Cook 7-deazapurine modified oligonucleotides
US6077668A (en) * 1993-04-15 2000-06-20 University Of Rochester Highly sensitive multimeric nucleic acid probes
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
WO1996011937A1 (en) * 1994-10-14 1996-04-25 Stratagene Porphyrin labeling of polynucleotides
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
DE4438918A1 (de) 1994-11-04 1996-05-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
US5801155A (en) 1995-04-03 1998-09-01 Epoch Pharmaceuticals, Inc. Covalently linked oligonucleotide minor grove binder conjugates
US6312894B1 (en) 1995-04-03 2001-11-06 Epoch Pharmaceuticals, Inc. Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders
US20010018514A1 (en) * 1998-07-31 2001-08-30 Mcgall Glenn H. Nucleic acid labeling compounds
US6143877A (en) 1997-04-30 2000-11-07 Epoch Pharmaceuticals, Inc. Oligonucleotides including pyrazolo[3,4-D]pyrimidine bases, bound in double stranded nucleic acids
WO1999040226A2 (en) 1998-02-04 1999-08-12 Perkin-Elmer Corporation Determination of a genotype of an amplification product at multiple allelic sites
US6127121A (en) 1998-04-03 2000-10-03 Epoch Pharmaceuticals, Inc. Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination
JP2001013103A (ja) * 1999-04-28 2001-01-19 Fuji Photo Film Co Ltd 走査型電気化学顕微鏡による試料核酸断片の検出方法および定量方法
JP4320104B2 (ja) * 1999-06-07 2009-08-26 富士フイルム株式会社 部分相補性核酸断片の検出方法
US6316230B1 (en) * 1999-08-13 2001-11-13 Applera Corporation Polymerase extension at 3′ terminus of PNA-DNA chimera

Also Published As

Publication number Publication date
WO2001038584A3 (en) 2001-10-25
JP2003527579A (ja) 2003-09-16
US6660845B1 (en) 2003-12-09
DE60044367D1 (de) 2010-06-17
US20040116689A1 (en) 2004-06-17
EP1232157B1 (de) 2010-05-05
WO2001038584A2 (en) 2001-05-31
US6972328B2 (en) 2005-12-06
EP1232157A2 (de) 2002-08-21
ES2344337T3 (es) 2010-08-25
AU1798901A (en) 2001-06-04
US20050239121A1 (en) 2005-10-27
CA2392033C (en) 2010-02-09
CA2392033A1 (en) 2001-05-31

Similar Documents

Publication Publication Date Title
ATE466864T1 (de) Nichtaggregierende, nichtausschaltende oligomere, nukleotid-analoga enthaltend; verfahren zu deren herstellung und verwendung
DE60033927D1 (de) L-ribo-lna analoge
ATE244259T1 (de) Verwendungen von fluoreszierenden n-nukleosiden und dessen analogen
ATE443136T1 (de) Methode für dna synthese
EP0963997A4 (de) Nucleotidanaloga
BR9407712A (pt) Métodos e composiçoes para sequenciamento eficaz de ácidos nuclêicos
DE60325016D1 (de) Oligonukleotide mit alternierenden segmenten und deren verwendungen
DE69808274D1 (de) Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie
WO2002022890A3 (en) Compositions, methods and kits for determining the presence of cryptosporidium organisms in a test sample
ATE194142T1 (de) Verfahren zur herstellung von nukleotiden
SI1644389T1 (sl) Pirimidinske spojine s fosfonatnimi skupinami kot antivirusni nukleotidni analogi
CA2506797A1 (en) Detectable labeled nucleoside analogs and methods of use thereof
WO2000029623A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
ATE242261T1 (de) Fluoreszend-konjugaten von nukleosiden und von nukleotiden, ihrer verfahren zur herstellung und ihrer verwendungen
ATE304541T1 (de) Verfahren zur herstellung von purinderivaten und dessen zwischenprodukte
DE69613984D1 (de) Für die protein-kinase a-spezifische modifizierte oligonukleotide und verfahren zur deren verwendung
DE60002989D1 (de) Verfahren zur herstellung von morpholinonukleotiden und verwendung derselben zur analyse und markierung von nukleinsäuresequenzen
ATE332971T1 (de) Typ ii dns polymerase aus pyrococcus abyssi
Yamada et al. A new modified cytosine base capable of base pairing with guanine using four hydrogen bonds
ATE300534T1 (de) Verfahren und zwischenverbindungen zur herstellung von imidazopyridinen
DE60335805D1 (de) Verfahren zur herstellung von 1,3-dioxolan-nucleosiden
DE60332874D1 (de) Pyren-gebundene pyrrolo(2,1-c)(1,4)benzodiazepin-derivate zur verwendung als antikrebsmittel
WO2000029622A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
DE69928543D1 (de) Pteridine-nukleotid-analoge
ATE388942T1 (de) Verfahren zur herstellung von 1-(pyrimidin-2- yl)propan-2-one derivaten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties